Table 4:
Class | Level of Evidence |
|
---|---|---|
2018 ACC/AHA Cholesterol Guidelines | ||
Screening Lp(a) in intermediate risk patients who are considering statin therapy | IIa | B-NR* |
2019 European Society of Cardiology Cholesterol Guidelines | ||
One time screening of Lp(a) in general to identify those at higher overall risk | IIa | C |
2019 National Lipid Association72 | ||
First degree relatives with premature ASCVD (men <55; women <65 years of age) | IIa | C-LD** |
A personal history of premature ASCVD | IIa | C-LD** |
Suspected FH or primary severe hypercholesterolemia (LDL-C ≥ 190 mg/dL) | IIa | B-NR* |
To aid in risk discussion for intermediate risk patients ages 40-75 | IIa | B-NR* |
Identify cause of less than expected LDL-C lowering | IIb | C-LD** |
Use as cascade screening in family members with severe hypercholesterolemia | IIb | C-LD** |
Identify risk of progressive aortic stenosis | IIb | C-LD** |
Nonrandomized data
Limited data